98%
921
2 minutes
20
Infected wounds are a complex disease involving bacterial infections and dysregulated inflammation. However, current research has mostly focused on bacterial inhibition rather than on inflammation. Thus, combined therapeutic strategies with anti-bacterial and anti-inflammation efficacies are urgently needed. Antibiotics are the main treatment strategy for infections. However, the excessive use of antibiotics throughout the body can cause serious side effects. In addition, miRNA-based therapeutics are superior for the treatment of wounds, but their rapid degradation and poor cellular uptake limit their clinical application. Tetrahedral framework DNA (tFNA) is an ideal drug delivery system owing to its excellent stability and remarkable transport ability. Herein, a novel multi-functional miRNA and antibiotic co-delivery system based on tFNA is presented for the first time, called B/L. B/L has heightened resistance to serum and excellent codelivery ability. After transdermal administration, B/L can specifically target TNF receptor-associated factor 6(TRAF6) and IL-1receptor-associated kinase 1(IRAK1), thereby regulating nuclear factor kappa-B (NF-𝜿B) and thus effectively reducing inflammation and promoting the healing of infected wounds. This novel multi-functional co-delivery system provides a versatile, simple, biocompatible, and powerful platform for the personalized and combined treatment of multiple diseases.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/smll.202406629 | DOI Listing |
Drug Dev Res
September 2025
School of Pharmacy, The University of Jordan, Amman, Jordan.
Cancer treatment faces challenges like nonselective toxicity and drug resistance, prompting the need for innovative therapies. This study aimed to develop liposomal formulations for co-delivery of empagliflozin and rutin, evaluating their anticancer and antioxidant efficacy. PEGylated empagliflozin-loaded nanoliposomes (Empa-NLs) and empagliflozin-rutin co-loaded nanoliposomes (Empa-Rut NLs) were synthesized using the thin-film hydration technique.
View Article and Find Full Text PDFBiomaterials
September 2025
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), Xiamen University, Xiamen 361005, China.
Retinal neovascularization is one of the most prevalent fundus neovascular diseases, affecting vision and potentially leading to severe complications, such as retinal detachment or irreversible blindness. Current treatments primarily involve intravitreal injections (IVT) of anti-vascular endothelial growth factor (anti-VEGF) agents. However, such treatment often requires repeated injections, develop incomplete responses, and are associated with adverse effects.
View Article and Find Full Text PDFPharm Res
September 2025
Department of BioNano Technology, Gachon BioNano Research Institute, Gachon University, Seongnam, Gyeonggi-Do, 13120, Republic of Korea.
Purpose: Adjuvants are critical for enhancing immune responses to recombinant protein-based vaccines, which typically exhibit weak immunogenicity. Microneedle array patches (MAPs) offer a promising method for intradermal delivery, but conventional Co-Delivery MAPs (containing antigen and adjuvant together) have limited loading capacity and potential undesirable interactions. Adjuvants may also trigger adverse reactions in sensitive populations.
View Article and Find Full Text PDFActa Biomater
September 2025
School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, Wuhan 430070, China; State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan, 430070, China; Shenzhen Institute of Wuhan University of Technol
Tumor heterogeneity poses formidable challenges to effective cancer therapy, necessitating the implementation of combination regimens to achieve enhanced antitumor efficacy. Optimizing drug administration sequences is pivotal to harnessing synergistic effects and achieving superadditive therapeutic outcomes (1 + 1 > 2). Erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, dynamically reprograms apoptotic pathways, sensitizing tumor cells to subsequent DNA-damaging agents like doxorubicin within a defined temporal window, thereby augmenting chemotherapy efficacy.
View Article and Find Full Text PDFJ Mater Chem B
September 2025
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Icariside II (ICAII), a bioactive compound derived from Epimedii Folium, exhibits promising anti-tumor activity but encounters challenges in its clinical application due to its poor solubility and low bioavailability. Thus, this study developed a novel carrier-free co-delivery system of ICAII and doxorubicin (DOX) through their self-assembly into nanofibers. ICAII combined with DOX nanofibers (ICAII-DOX NFs), and ICAII-DOX/TPGS NFs (with TPGS as a stabilizer) were systematically characterized for their physicochemical properties, including size distribution, morphology, and molecular interactions.
View Article and Find Full Text PDF